Cover Image
市場調查報告書

社區性感染症:全球臨床實驗檢討

Community-Acquired Infections Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 320829
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
社區性感染症:全球臨床實驗檢討 Community-Acquired Infections Global Clinical Trials Review, H1, 2017
出版日期: 2017年06月30日 內容資訊: 英文 47 Pages
簡介

社區性感染症,不是在醫療現場和住院中感染的感染疾病。許多情況下,社區性感染症,與在院內,影響從疾病和受傷回復的患者的微生物引起的疾病有區別。市內呼吸系統感染疾病,作用於流感菌和肺炎鏈球菌,通常對抗生素敏感。

本報告提供社區性感染症的治療藥相關臨床實驗調查分析、臨床實驗數及受驗人數、各階段及各方面狀況、有潛力的企業、正在開發的治療藥的資訊、臨床實驗簡介等相關的系統性資訊。

目錄

簡介

各地區的臨床實驗

  • 各國臨床實驗趨勢
    • 亞太地區的主要國家
    • 歐洲的主要國家
    • 北美的主要國家
    • 中東、非洲的主要國家
    • 中南美的主要國家

G7各國的臨床實驗:社區性感染症對感染性疾病臨床實驗的比例

G7各國的臨床實驗:各Phase

G7各國的臨床實驗:各階段

E7各國的臨床實驗:社區性感染症對感染性疾病臨床實驗的比例

E7各國的臨床實驗:各Phase

E7各國的臨床實驗:各階段

各方面的臨床實驗

各階段臨床實驗

各評估項目臨床實驗

未完成的臨床實驗

一定期間採用的實驗對象

各贊助商類型臨床的實驗

有潛力的贊助商

  • 社區性感染症的治療藥參與臨床實驗的主要企業

有前途藥物

臨床實驗簡介

  • 主要企業臨床實驗概要
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Panacea Biotec Limited
    • 第一三共
    • Tetraphase Pharmaceuticals Inc.
    • TaiGen Biopharmaceuticals Holdings Limited
    • Janssen Research & Development, LLC
    • Dong Wha Pharma Co., Ltd.
    • Cubist Pharmaceuticals, Inc.
    • Belpharma S.A.
  • 主要大學、研究機關、醫院臨床實驗概要
    • Hanyang University Medical Center
    • Ewha Womans University
    • Kyungpook National University
    • Katholieke Universiteit Leuven
    • Rennes University Hospital
    • University of Milan

主要的臨床簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4324CTIDB

GlobalData's clinical trial report, "Community-Acquired Infections Global Clinical Trials Review, H1, 2017" provides an overview of Community-Acquired Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Community-Acquired Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 21
  • Clinical Trials in E7 Countries by Trial Status 22
  • Clinical Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Community-Acquired Infections Therapeutics Clinical Trials 30
  • Prominent Drugs 32
  • Clinical Trial Profile Snapshots 33

Appendix 45

  • Abbreviations 45
  • Definitions 45
  • Research Methodology 46
  • Secondary Research 46
  • About GlobalData 47
  • Contact Us 47
  • Source 47

List of Tables

List of Tables

  • Community-Acquired Infections Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Community-Acquired Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Community-Acquired Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Community-Acquired Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Community-Acquired Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Community-Acquired Infections Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Community-Acquired Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
  • Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 16
  • Community-Acquired Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Community-Acquired Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 20
  • Community-Acquired Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Community-Acquired Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Community-Acquired Infections Therapeutics, Global, Clinical Trials by Phase, 2017* 23
  • Community-Acquired Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 25
  • Community-Acquired Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
  • Community-Acquired Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Community-Acquired Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 29
  • Community-Acquired Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
  • Community-Acquired Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures

List of Figures

  • Community-Acquired Infections Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Community-Acquired Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Community-Acquired Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Community-Acquired Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Community-Acquired Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Community-Acquired Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Community-Acquired Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 14
  • Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 15
  • Community-Acquired Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Community-Acquired Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Community-Acquired Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 19
  • Community-Acquired Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 21
  • Community-Acquired Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 22
  • Community-Acquired Infections Therapeutics, Global, Clinical Trials by Phase (%), 2017* 23
  • Community-Acquired Infections Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Community-Acquired Infections Therapeutics Clinical Trials, Global, by End Point Status, 2017* 26
  • Community-Acquired Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Community-Acquired Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Community-Acquired Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
  • Community-Acquired Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
  • GlobalData Methodology 46
Back to Top